Although about miR186 regulation of Twist1 expression implicating in cisplatin resistance in ovarian cancer has been recently reported [34], our data demonstrate that miR186 plays a tumor suppressive role in PCa by inhibiting tumorigenesis and metastasis, and its expression level is reversely correlated to the clinical grade and pathological grading, and the low miR186 expression is correlated with poor patient survival. This evidence concerns the gene TWIST1 and ovarian cancer.